PCRX stock forecast, quote, news & analysis

PCRX's RSI Indicator recovers from oversold territory

The RSI Oscillator for PCRX moved out of oversold territory on August 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 33 of the 39 cases the stock moved higher. This puts the odds of a move higher at 85%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for PCRX crossed bullishly above the 50-day moving average on September 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.

Following a +0.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCRX advanced for three days, in 215 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PCRX as a result. In 65 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The Moving Average Convergence Divergence Histogram (MACD) for PCRX turned negative on September 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 37 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.

PCRX moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. PCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.504) is normal, around the industry mean (46.728). P/E Ratio (72.429) is within average values for comparable stocks, (93.360). PCRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). PCRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.441) is also within normal values, averaging (176.516).

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.